![Q2 2024 Outlook Report_hero](https://www.citeline.com/-/media/citeline/resources/2024/04/q2-2024-outlook-report/images/q2-2024-outlook-report_hero.jpg?la=en&h=528&w=1340&hash=D3935D4613CDDFEC56D7E1CB41509BD5)
![Q2 2024 Outlook Report_hero](https://www.citeline.com/-/media/citeline/resources/2024/04/q2-2024-outlook-report/images/q2-2024-outlook-report_hero.jpg?la=en&h=528&w=1340&hash=D3935D4613CDDFEC56D7E1CB41509BD5)
In this report, we cover catalysts from 22 drugs, devices, diagnostics, and deals expected to occur in Q2 2024. For each drug, the likelihood of Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group are provided.